Identifying modifiers for plasmacytoma susceptibility

Funded Activity Summary

Many oncogenes and tumour suppressor genes have been identified. Activation or deletion of these genes can have profound effects on the control of cell growth and result in tumours. Many tumour suppressor genes give carriers an elevated risk of disease. However in many cases the incidence of these mutations causing cancer is much lower than would be expected, due to other influencing factors. This project aims to try and understand the reasons behind this in a mouse model of cancer, plasmacytomas. Modifers of tumour incidence are proposed for human disease but very little is known about the identity of the genes involved or in the biological pathways regulating tumour incidence. The search for these genes in humans is difficult. We have begun studies to find modifiers of tumourigenesis using the E -v-abl transgenic model of plasmacytomas. This is the mouse equivalent of multiple myeloma. Studies have shown that some strains of mice have markedly different incidences of tumours. C57BL-6 animals are less susceptible with 20% of animals developing tumour by 12 months of age. In contrast, 90% of transgenic animals on the BALB-c background develop tumour by 12 months of age. There is also a significant sex difference with males being more susceptible than females. There is a similar difference in susceptibility in humans to multiple myeloma.

Funded Activity Details

Start Date: 01-01-2003

End Date: 01-01-2005

Funding Scheme: NHMRC Project Grants

Funding Amount: $265,500.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology And Carcinogenesis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Cancer | Determining genetic susceptibility to disease | Genetics | Genetics of complex diseases | Mouse models of cancer | Multiple myeloma | Myeloma | Tumour suppressor gene | Tumour suppressor genes

Related Links